Industry: Pharmaceuticals (See others in industry)
Address:| Date | FilingType | Incremental Cash | Link to Raw Filing | |||
|---|---|---|---|---|---|---|
| 2025-09-09 | Amended | $119,850,000 | Unknown | Equity Only | SEC link | |
| 2025-05-05 | Amended | $68,880,305 | $35,212,123 | Equity Only | 06b | SEC link |
| 2024-05-06 | Amended | $33,668,182 | $16,818,182 | Equity Only | 06b | SEC link |
| 2024-01-25 | New | $16,850,000 | $16,850,000 | Equity Only | 06b | SEC link |
| Name | Role |
|---|---|
| Robert Alexander | Executive |
| Nathan Bryson | Executive |
| Michael Ehlers | Director |
| Ansbert Gadicke | Director |
| Alon Lazarus | Director |
| Ellen Lubman | Director |
| Gregory Mayes | Director, Executive |
| Briggs Morrison | Director |
| Mark Pollack | Executive |
| Natalie Sacks | Director |
| Edward Smith | Executive |
| Mark Theeuwes | Executive |